- Home
- NBR vs CAPR Comparison
NBR vs CAPR Comparison
Compare NBR & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBR
- CAPR
- Stock Information
- Founded
- NBR 1952
- CAPR 2005
- Country
- NBR Bermuda
- CAPR United States
- Employees
- NBR N/A
- CAPR N/A
- Industry
- NBR Oil & Gas Production
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NBR Energy
- CAPR Health Care
- Exchange
- NBR Nasdaq
- CAPR Nasdaq
- Market Cap
- NBR 633.5M
- CAPR 525.3M
- IPO Year
- NBR N/A
- CAPR N/A
- Fundamental
- Price
- NBR $42.82
- CAPR $9.74
- Analyst Decision
- NBR Hold
- CAPR Strong Buy
- Analyst Count
- NBR 7
- CAPR 7
- Target Price
- NBR $73.33
- CAPR $39.29
- AVG Volume (30 Days)
- NBR 483.9K
- CAPR 1.5M
- Earning Date
- NBR 04-23-2025
- CAPR 03-19-2025
- Dividend Yield
- NBR N/A
- CAPR N/A
- EPS Growth
- NBR N/A
- CAPR N/A
- EPS
- NBR N/A
- CAPR N/A
- Revenue
- NBR $2,930,126,000.00
- CAPR $22,270,465.00
- Revenue This Year
- NBR $13.54
- CAPR $34.33
- Revenue Next Year
- NBR $8.39
- CAPR $246.72
- P/E Ratio
- NBR N/A
- CAPR N/A
- Revenue Growth
- NBR N/A
- CAPR N/A
- 52 Week Low
- NBR $34.42
- CAPR $3.52
- 52 Week High
- NBR $105.96
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- NBR 46.99
- CAPR 34.89
- Support Level
- NBR $40.08
- CAPR $8.90
- Resistance Level
- NBR $45.69
- CAPR $13.81
- Average True Range (ATR)
- NBR 2.42
- CAPR 1.18
- MACD
- NBR 0.46
- CAPR -0.34
- Stochastic Oscillator
- NBR 48.84
- CAPR 14.36
About NBR Nabors Industries Ltd.
Nabors Industries Ltd owns and operates land-based drilling rig fleets and is a provider of offshore platform rigs in the United States and international markets. It also provides performance tools, directional drilling services, tubular running services, and technologies. The company has four reportable segments: U.S. Drilling, International Drilling, Drilling Solutions, and Rig Technologies. The key revenue of the company is generated from International Drilling.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.